XSpray Pharma (Sweden) Price Prediction
| XSPRAY Stock | SEK 42.10 0.10 0.24% |
Oversold Vs Overbought
29
Oversold | Overbought |
Using XSpray Pharma hype-based prediction, you can estimate the value of XSpray Pharma AB from the perspective of XSpray Pharma response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in XSpray Pharma to buy its stock at a price that has no basis in reality. In that case, they are not buying XSpray because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
XSpray Pharma after-hype prediction price | SEK 42.1 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
XSpray |
XSpray Pharma After-Hype Price Prediction Density Analysis
As far as predicting the price of XSpray Pharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in XSpray Pharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of XSpray Pharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
XSpray Pharma Estimiated After-Hype Price Volatility
In the context of predicting XSpray Pharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on XSpray Pharma's historical news coverage. XSpray Pharma's after-hype downside and upside margins for the prediction period are 38.75 and 45.45, respectively. We have considered XSpray Pharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
XSpray Pharma is very steady at this time. Analysis and calculation of next after-hype price of XSpray Pharma AB is based on 3 months time horizon.
XSpray Pharma Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as XSpray Pharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading XSpray Pharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with XSpray Pharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.25 | 3.35 | 0.00 | 0.00 | 0 Events / Month | 0 Events / Month | Any time |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
42.10 | 42.10 | 0.00 |
|
XSpray Pharma Hype Timeline
XSpray Pharma AB is at this time traded for 42.10on Stockholm Exchange of Sweden. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.0. XSpray is projected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is projected to be very small, whereas the daily expected return is at this time at -0.25%. %. The volatility of related hype on XSpray Pharma is about 0.0%, with the expected price after the next announcement by competition of 42.10. About 47.0% of the company outstanding shares are owned by insiders. The book value of XSpray Pharma was at this time reported as 24.95. The company recorded a loss per share of 5.18. XSpray Pharma AB had not issued any dividends in recent years. Assuming the 90 days trading horizon the next projected press release will be any time. Check out XSpray Pharma Basic Forecasting Models to cross-verify your projections.XSpray Pharma Related Hype Analysis
Having access to credible news sources related to XSpray Pharma's direct competition is more important than ever and may enhance your ability to predict XSpray Pharma's future price movements. Getting to know how XSpray Pharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how XSpray Pharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| XBRANE | Xbrane Biopharma AB | 0.00 | 0 per month | 4.57 | 0.02 | 12.50 | (9.09) | 31.31 | |
| HNSA | Hansa Biopharma AB | 0.00 | 0 per month | 0.00 | (0.25) | 3.40 | (5.68) | 21.12 | |
| CANTA | Cantargia AB | 0.00 | 0 per month | 0.00 | (0.19) | 6.11 | (5.10) | 48.23 | |
| VICO | Vicore Pharma Holding | 0.00 | 0 per month | 0.00 | (0.14) | 3.39 | (4.36) | 52.59 | |
| BIOA-B | BioArctic AB | 0.00 | 0 per month | 2.89 | 0.06 | 6.39 | (4.55) | 39.02 |
XSpray Pharma Additional Predictive Modules
Most predictive techniques to examine XSpray price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for XSpray using various technical indicators. When you analyze XSpray charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About XSpray Pharma Predictive Indicators
The successful prediction of XSpray Pharma stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as XSpray Pharma AB, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of XSpray Pharma based on analysis of XSpray Pharma hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to XSpray Pharma's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to XSpray Pharma's related companies.
Story Coverage note for XSpray Pharma
The number of cover stories for XSpray Pharma depends on current market conditions and XSpray Pharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that XSpray Pharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about XSpray Pharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Other Macroaxis Stories
Our audience includes start-ups and big corporations as well as marketing, public relation firms, and advertising agencies, including technology and finance journalists. Our platform and its news and story outlet are popular among finance students, amateur traders, self-guided investors, entrepreneurs, retirees and baby boomers, academic researchers, financial advisers, as well as professional money managers - a very diverse and influential demographic landscape united by one goal - build optimal investment portfolios
Story Categories
Currently Trending Categories
XSpray Pharma Short Properties
XSpray Pharma's future price predictability will typically decrease when XSpray Pharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of XSpray Pharma AB often depends not only on the future outlook of the potential XSpray Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. XSpray Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 19.2 M | |
| Cash And Short Term Investments | 271.9 M |
Complementary Tools for XSpray Stock analysis
When running XSpray Pharma's price analysis, check to measure XSpray Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XSpray Pharma is operating at the current time. Most of XSpray Pharma's value examination focuses on studying past and present price action to predict the probability of XSpray Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XSpray Pharma's price. Additionally, you may evaluate how the addition of XSpray Pharma to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |